Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
IPO Year: 2020
Exchange: NASDAQ
Website: zentalis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2024 | $4.00 | Underperform → Neutral | Wedbush |
| 6/20/2024 | $28.00 → $5.00 | Buy → Neutral | UBS |
| 6/18/2024 | $42.00 → $6.00 | Buy → Hold | Jefferies |
| 6/18/2024 | $38.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/18/2024 | $15.00 → $4.00 | Neutral → Underperform | Wedbush |
| 6/18/2024 | Overweight → Equal Weight | Wells Fargo | |
| 11/8/2023 | $38.00 → $12.00 | Outperform → Neutral | Wedbush |
| 11/7/2023 | $15.00 | Outperform → Market Perform | Leerink Partners |
| 7/12/2022 | Outperform | Cowen | |
| 4/6/2022 | $67.00 | Overweight | Wells Fargo |
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
DEFA14A - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
S-8 - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
SCHEDULE 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SCHEDULE 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
DEFA14A - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00
UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously
Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously
Morgan Stanley downgraded Zentalis Pharma from Overweight to Equal-Weight and set a new price target of $8.00 from $38.00 previously
Wedbush downgraded Zentalis Pharma from Neutral to Underperform and set a new price target of $4.00 from $15.00 previously
Wells Fargo downgraded Zentalis Pharma from Overweight to Equal Weight
Wedbush downgraded Zentalis Pharma from Outperform to Neutral and set a new price target of $12.00 from $38.00 previously
Leerink Partners downgraded Zentalis Pharma from Outperform to Market Perform and set a new price target of $15.00
Cowen initiated coverage of Zentalis Pharma with a rating of Outperform
Wells Fargo initiated coverage of Zentalis Pharma with a rating of Overweight and set a new price target of $67.00
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Management to host conference call today at 8:00 am ET SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's enteri
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual'
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the first quarter 2025 and highlighted recent oper
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously d
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company's common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individu
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced four poster presentations at the 2025
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug conjugates (ADCs) demonstrating synergistic antitumor effects SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a restructuring of its business operations and research and development organ
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer. "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies," said Julie Eastland, Chief Executive Officer. "To support this goal, we are continuing to tune our leadership team and today announced the appointment of two talented leaders with a strong track record o
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2024, and highlighted recent corporate accomplishments. "While we faced challenges this quarter with regards to the ongoing partial clinical hold on azenosertib, we remain steadfast in our confidence in the program's t
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies. "We are pleased to have Luke join our Board of Directors and contribute to the Company's pipeline
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis' long-term portfolio strategy. Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway. "Kimberly brings an o
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Iris Roth, PhD, as Chief Operating Officer (COO). Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies, successfully advancing the development of multiple investigational therapies in oncology. "I am incredibly pleased to welcome Iris to Zentalis, rounding out our management team wit
NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Mark Lackner, PhD, as Chief Translational Officer, Head of Biomarker Strategy. Dr. Lackner, an esteemed cancer biologist, joins Zentalis with over two decades of oncology-focused drug development expertise, including significant experience in biomarker discovery and clinical biomarker strategies. "This year, we have prioritized strengthening our executive team and s
NEW YORK and SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Carrie Brownstein, MD, as Chief Medical Officer (CMO), effective October 3, 2022. Dr. Brownstein, a leading oncologist and hematologist by training, joins Zentalis with over two decades of medical and biopharmaceutical experience executing clinical program strategies across all phases of product development. "We are honored to welcome Carrie to our team as CMO, whe
NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Jan Skvarka, PhD, MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to Zentalis. "We are excited to welcome Jan, an experienced life sciences leader, to our Board of Directors," said Dr. Kimberly Blackwell, Chief Executive Officer of Zenta